GlassScriptPhysician profile
Richard Buckler
NPI 1528051224
$2,066.96
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,552 · 2020: $515.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $364.44 | 2019-2020 | |
| Emd Serono, INC. | $257.61 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $156.77 | 2019-2020 | |
| Akcea Therapeutics, INC. | $151.58 | 2019 | |
| Genentech USA, INC. | $149.43 | 2019 | |
| Neuronetics, INC. | $130.91 | 2020 | |
| Genzyme Corporation | $95.50 | 2019 | |
| Acadia Pharmaceuticals INC | $76.75 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $74.56 | 2019-2020 | |
| Allergan, INC. | $68.99 | 2019-2020 | |
| Ucb, INC. | $58.63 | 2019 | |
| Amgen INC. | $58.04 | 2019 | |
| Assertio Therapeutics, INC. | $53.44 | 2019 | |
| Lilly USA, LLC | $53.06 | 2019-2020 | |
| Eisai INC. | $45.67 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $41.72 | 2019 | |
| Upsher-Smith Laboratories LLC | $38.09 | 2019 | |
| Csl Behring | $36.96 | 2019 | |
| Tersera Therapeutics LLC | $30.00 | 2019 | |
| Mallinckrodt Hospital Products INC. | $22.31 | 2020 | |
| Janssen Pharmaceuticals, INC | $20.80 | 2020 | |
| Adamas Pharmaceuticals, INC. | $20.34 | 2019 | |
| Alexion Pharmaceuticals, INC. | $18.87 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.48 | 2020 | |
| Biogen, INC. | $12.72 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.29 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Buckler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.